Aprea Therapeutics downgraded by Berenberg
$APRE
Biotechnology: Pharmaceutical Preparations
Health Care
Berenberg downgraded Aprea Therapeutics from Buy to Hold
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/20/2021 | Neutral → Underweight | JP Morgan | |
| 8/16/2021 | Buy → Hold | Berenberg | |
| 8/16/2021 | $6.00 → $4.00 | Neutral | HC Wainwright & Co. |
| 8/13/2021 | $6.00 → $5.00 | Sector Perform | RBC Capital |
| 8/13/2021 | $5.00 → $3.00 | Equal-Weight → Underweight | Morgan Stanley |
4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)
4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)
4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)
8-K - Aprea Therapeutics, Inc. (0001781983) (Filer)
SCHEDULE 13G/A - Aprea Therapeutics, Inc. (0001781983) (Subject)
10-Q - Aprea Therapeutics, Inc. (0001781983) (Filer)
JP Morgan downgraded Aprea Therapeutics from Neutral to Underweight
Berenberg downgraded Aprea Therapeutics from Buy to Hold
HC Wainwright & Co. reiterated coverage of Aprea Therapeutics with a rating of Neutral and set a new price target of $4.00 from $6.00 previously
4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)
4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)
4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)
ATRN-119, our ATR inhibitor, exhibits early evidence of single agent, anti-tumor activity and is progressing toward the recommended Phase 2 dose (RP2D) in the ongoing ABOYA-119 clinical trial Three patients in the 550 mg twice daily cohort in the ongoing ABOYA-119 clinical trial demonstrated tumor shrinkage of 7%, 14% and 21% ACESOT-1051, the Phase 1 trial of WEE1 inhibitor APR-1051, continues to advance, with patients now being dosed at 100 mg once daily $19.3 million in cash and cash equivalents as of March 31, 2025, providing runway into early Q2 2026 DOYLESTOWN, Pa., May 14, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", o
Two programs with clinical data readouts in 2H/2025 Phase 1 clinical trial of ADI-001 in autoimmune diseases ongoing with preliminary clinical data expected in 2H/2025; Trial now open for enrollment to patients with lupus nephritis (LN) and systemic lupus erythematosus (SLE) Preliminary data for ongoing ADI-270 Phase 1 clinical trial in patients with metastatic/advanced clear cell renal cell carcinoma (ccRCC) expected in 2H/2025 Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the first quarter ended M
--Mr. Grissinger brings more than four decades of leadership experience in pharmaceutical business development and strategic transactions-- Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of Michael Grissinger to its Board of Directors. Mr. Grissinger brings more than four decades of experience in business development, strategy, and M&A leadership roles at global pharmaceutical companies. "We are honored to welcome Michael to our Board of Directors," said Chen Schor, President and Chief Executive Officer of Adicet Bio. "His extensive